Promising Lung Cancer Treatment Results Developed By This Company
Immutep's Efti and KEYTRUDA®: A Promising Combination for Non-Small Cell Lung Cancer Patients
The biotechnology sector is buzzing with the latest exciting development from Immutep Limited (Ticker: $IMMP). The company has recently announced that its lead product candidate, eftilagimod alpha (Efti), in combination with Merck's KEYTRUDA®, has shown significant overall survival benefit for patients with metastatic non-small cell lung cancer (NSCLC).
